Outset Medical, Inc. (NASDAQ:OM) Given Average Rating of “Moderate Buy” by Analysts

Shares of Outset Medical, Inc. (NASDAQ:OM) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.00.

A number of analysts have recently commented on OM shares. BTIG Research cut their target price on shares of Outset Medical from $39.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, November 11th. Stifel Nicolaus set a $14.00 price objective on Outset Medical and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Wall Street Zen cut Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Royal Bank Of Canada lowered their price target on Outset Medical from $22.00 to $17.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday.

Outset Medical Price Performance

Shares of NASDAQ OM opened at $4.39 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09. The firm has a fifty day moving average of $10.34 and a 200 day moving average of $14.58. The firm has a market cap of $79.68 million, a PE ratio of -0.34 and a beta of 2.03. Outset Medical has a one year low of $4.00 and a one year high of $25.35.

Hedge Funds Weigh In On Outset Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in Outset Medical in the 2nd quarter valued at about $34,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Outset Medical in the second quarter valued at approximately $35,000. BNP Paribas Financial Markets increased its holdings in shares of Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Outset Medical in the second quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund purchased a new position in Outset Medical during the second quarter worth approximately $108,000.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.